Skip navigation
BelSU DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bsu.edu.ru/handle/123456789/19835
Title: Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology
Authors: Ragulina, V. A.
Kostina, D. A.
Dovgan, A. P.
Burda, Y. E.
Nadezhdin, S. V.
Keywords: medicine
pharmacology
nuclear factor kappa B
NF-κB
endothelial dysfunction
ischemia-reperfusion
pharmacological correction
comorbidity
Issue Date: 2017
Citation: Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology / V. A. Ragulina [и др.] // Research result. Pharmacology and clinical pharmacology. - 2017. - Vol.3, №1.-P. 114-124. - DOI : 10.18413/2500-235X-2017-3-1-114-124. - Refer.: p. 120-124.
Abstract: The nuclear factor kappa B (NF-κB) is one of transcription factors. A high interest in studying the biological role of the signal system and its contribution to the development of cardiovascular, oncological and autoimmune diseases is obvious. A number of stimuli (proinflammatory cytokines: tumor necrosis factor α, interleukin 1β, ligand CD40 and others) trigger the canonical and non-canonical pathways of NF-κB signaling, which increase the expression of genes regulating synthesis of cytokines and chemokines, cell proliferation and differentiation, angiogenesis, immune reactions and apoptosis. However, pathological activation of NF-κB violates the balance of substances participating in the normal activity of the cardiovascular system. This leads to the development and progression of endothelium-associated pathology and comorbidity
URI: http://dspace.bsu.edu.ru/handle/123456789/19835
Appears in Collections:Research Result. Pharmacology and Clinical Pharmacology

Files in This Item:
File Description SizeFormat 
Ragulina_Nuclear_17.pdf672.89 kBAdobe PDFView/Open
Show full item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.